Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269828 · ClinicalTrials.gov registry record · Phase 3
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
A Phase 3 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00269828: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.
NCT00269828 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00269828, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Interventions
- DRUG paclitaxel
- DRUG paclitaxel poliglumex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00269828
The ClinicalTrials.gov registry entry for NCT00269828 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.
NCT00269828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00269828 about?
NCT00269828 is a clinical study titled "A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.". This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
What is the current status of trial NCT00269828?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2005-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00269828?
The interventions under investigation include: paclitaxel (DRUG), paclitaxel poliglumex (DRUG).
Who is sponsoring clinical trial NCT00269828?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.